Trastuzumab/docetaxel-induced nail dystrophy.
Alexandrescu
Doru T
DT
New York Medical College, Our Lady of Mercy Medical Center, Comprehensive Cancer Center, Department of Dermatology, Bronx, NY 10466, USA. mddoru@hotmail.com
Vaillant
Juan
J
Wiernik
Peter H
PH
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D000077143:Docetaxel; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008875:Middle Aged; D009260:Nail Diseases / Q000139:chemically induced*; D009362:Neoplasm Metastasis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects*; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000077143:Docetaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids; D000068878:Trastuzumab